Evidence map›Paper›PMID 34137730›Full record

ArticleEndocrine connections2021

Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men.

Nandini Shankara Narayana, Lam P Ly, Veena Jayadev, Carolyn Fennell, Sasha Savkovic, Ann J Conway, David J Handelsman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine connections, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health.International journal of molecular sciences · 2022
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Nandini Shankara NarayanaAndrology Department, Concord Hospital and, ANZAC Research Institute, University of Sydney, Sydney, Australia.ORCID 0000-0003-0881-4116
Lam P LyAndrology Department, Concord Hospital and, ANZAC Research Institute, University of Sydney, Sydney, Australia.
Veena JayadevAndrology Department, Concord Hospital and, ANZAC Research Institute, University of Sydney, Sydney, Australia.
Carolyn FennellAndrology Department, Concord Hospital and, ANZAC Research Institute, University of Sydney, Sydney, Australia.
Sasha SavkovicAndrology Department, Concord Hospital and, ANZAC Research Institute, University of Sydney, Sydney, Australia.
Ann J ConwayAndrology Department, Concord Hospital and, ANZAC Research Institute, University of Sydney, Sydney, Australia.
David J HandelsmanAndrology Department, Concord Hospital and, ANZAC Research Institute, University of Sydney, Sydney, Australia.
University of Sydney · AUAnzac Research Institute · AUConcord Repatriation General Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo define the optimized inter-injection interval of injectable testosterone undecanoate (TU) treatment for hypogonadal and transmen based on individual dose titration in routine clinical practice. DESIGN AND

methodsA prolective observational study of consecutive TU injections in men undergoing testosterone replacement therapy for pathological hypogonadism or masculinization of female-to-male transgender (transmen) subject to individual dosing titration to achieve a stable replacement regimen.

resultsFrom 2006 to 2019, 6899 injections were given to 325 consecutive patients. After excluding the 6-week loading dose, 6300 injections were given to 297 patients who had at least three and a median of 14 injections. The optimal injection interval (mean of last three injection intervals) had a median of 12.0 weeks (interquartile range 10.4-12.7 weeks). The interval was significantly influenced by age and body size (body surface area, BSA) but not by diagnosis or trough serum LH, FSH, and SHBG. Longer (≥14 weeks; 68/297, 23%), but not shorter (≤10 weeks; 22/297, 7.4%), intervals were weakly correlated with age but not diagnosis or other covariables. Low blood hemoglobin increased with trough serum testosterone to reach plateau once testosterone was about 10 nmol/L or higher.

conclusionOptimal intervals between TU injection after individual titration resulted in the approved 12-week interval in 70% of patients with only minor influence for clinical application of BSA and not of trough serum LH, FSH, and SHBG. Individually optimized inter-injection interval did not differ between men with primary or secondary hypogonadism or transmen.

Indexed as

androgenhypogonadismintra-muscular injectiontestosteronetransgender

Identifiers

PMID34137730
PMCPMC8346198
OpenAlexW3170473177

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.